Medplus Health (MEDPLUS)

FairStock Score: 32/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me define a great investment: a business with durable advantages, sensible earnings power, and a price that leaves room for error. Medplus fails that final test, and I have doubts about the first. Pharmacy retail is a hard, low-margin business. Last quarter, Medplus earned ₹58 crore on ₹1,806 crore of sales — barely a 3.2% net margin. The company is growing: sales are up 15.67% and profits up 25.98% over the year. The Piotroski score of 7/9 suggests the operational engine is not broken. Debt-to-equity of 0.65 is manageable, and ROCE of 10.28% is respectable. Promoter holding of 40.29% means skin in the game. But return on equity is just 4.94%; that is miserable for a company being priced like a winner. At ₹907, the stock trades at 49.16 times earnings and 9.16 times book value, and the PEG ratio of 2.36 tells me the market has already paid for years of success. There is no dividend to cushion the wait. The FairStock Score of 29/100 labels this risky, and I agree. Graham would insist on margin of safety; at today's price, I see none. A good growth company can still be a bad investment if you pay too much. I would need a much lower price to turn this into a decision. Until ROE improves meaningfully or the stock falls to a valuation that compensates for the thin margins, Medplus is more risk than reward. I can wait.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer